person · Reporting owner

Fain Eric S

Disclosed activity across 3 companies

Tapewire entity: 16158
SEC CIK: 0001402222

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Orchestra BioMed Holdings, Inc.OBIO · Entity 434	Director	August 12, 2026	August 14, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Orchestra BioMed Holdings, Inc.

Report date August 12, 2026 · Filed August 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.0001 per shareSEC Table I · non-derivative	IndirectBy the Fain Living Trust	99,630	Reported balance After 2026-08-12 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-08-12 · Tax withholding · Disposed 5,145 · Balance 99,630 F1: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ABBOTT LABORATORIES

Report date July 21, 2017 · Filed September 29, 2017 · Amendment

Section 16 reporting ended · disclosed 2017-09-29. Current position is not established by this disclosure.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common shares without par valueSEC Table I · non-derivative	Direct	493,961	Reported balance After 2017-07-21 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2017-07-21 · Disposition to issuer · Disposed 23,085 · Balance 493,961

ST JUDE MEDICAL, LLC

Report date January 04, 2017 · Filed January 06, 2017

Section 16 reporting ended · disclosed 2017-01-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-01-04 transaction · row 1 1 source row Row 1 · 2017-01-04 · Disposition to issuer · Disposed 130,716 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.59 · Expires 2017-12-14	Direct	Reported balance After 2017-01-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-01-04 · Disposition to issuer · Disposed 140,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.65 · Expires 2018-12-14	Direct	Reported balance After 2017-01-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-01-04 · Disposition to issuer · Disposed 144,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.96 · Expires 2019-12-12	Direct	Reported balance After 2017-01-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-01-04 · Disposition to issuer · Disposed 200,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.27 · Expires 2020-12-10	Direct	Reported balance After 2017-01-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-01-04 · Disposition to issuer · Disposed 150,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.41 · Expires 2021-12-10	Direct	Reported balance After 2017-01-04 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-01-04 · Disposition to issuer · Disposed 85,156 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.08 · Expires 2022-12-08	Direct	Reported balance After 2017-01-04 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-01-04 · Disposition to issuer · Disposed 82,364 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.62 · Expires 2023-12-07	Direct	Reported balance After 2017-01-04 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2017-01-04 · Disposition to issuer · Disposed 104,408 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-01-04 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-01-04 · Disposition to issuer · Disposed 2,554 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-01-04 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2017-01-04 · Disposition to issuer · Disposed 4,678 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-01-04 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2017-01-04 · Disposition to issuer · Disposed 8,316 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.

F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.

F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.

F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 12, 2026 Filed Aug 14, 2026 20:16 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	Tax withholdingCommon Stock, par value $0.0001 per share	5,145	$4.42	$22,740.90	Disclosure SEC source: 0001104659-26-097192 · tm2623285-3_4seq1.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 99,630 F1 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. Read SEC document
June 24, 2026 Filed Jun 25, 2026 20:21 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	Tax withholdingCommon Stock	4,261	$0.00	$0.00	Disclosure SEC source: 0001104659-26-077780 · tm2618965-6_4seq1.xml · nonDerivative · entry 2 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 104,775 F2 · kind: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of RSUs. No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. Read SEC document
June 23, 2026 Filed Jun 25, 2026 20:21 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantStock Option (Right to Buy) · Derivative	21,277	$0.00 Strike: $4.04	$0.00	Disclosure SEC source: 0001104659-26-077780 · tm2618965-6_4seq1.xml · derivative · entry 3 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 21,277 Underlying: Common Stock · 21,277 shares Expires 2036-06-23 F3 · derivative.exercise_date: The stock options will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date. Read SEC document
June 23, 2026 Filed Jun 25, 2026 20:21 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantCommon Stock, par value $0.0001 per share ("Common Stock")	17,327	$0.00	$0.00	Disclosure SEC source: 0001104659-26-077780 · tm2618965-6_4seq1.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 109,036 F1 · shares: Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on June 23, 2026 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date. Read SEC document
May 14, 2026 Filed May 18, 2026 12:00 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	PurchaseCommon Stock, par value $0.0001 per share	20,000	$4.13	$82,600.00	Disclosure SEC source: 0001104659-26-063015 · tm2614903-1_4seq1.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 91,709 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.10 to $4.14. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
August 25, 2025 Filed Aug 25, 2025 23:04 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	PurchaseCommon Stock, par value $0.0001 per share	5,760	$2.61	$15,033.60	Disclosure SEC source: 0001104659-25-082638 · tm2524324-4_4seq1.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 71,709 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.60 to $2.61. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
August 07, 2025 Filed Aug 8, 2025 23:12 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantCommon Stock	7,500	$0.00	$0.00	Disclosure SEC source: 0001104659-25-075784 · tm2523004-5_4seq1.xml · nonDerivative · entry 2 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 58,449 F1 · shares: Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date. Read SEC document
August 07, 2025 Filed Aug 8, 2025 23:12 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantCommon Stock, par value $0.0001 per share ("Common Stock")	7,500	$0.00	$0.00	Disclosure SEC source: 0001104659-25-075784 · tm2523004-5_4seq1.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 F1 · shares: Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date. Read SEC document
June 26, 2025 Filed Jun 27, 2025 21:10 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	SaleCommon Stock, par value $0.0001 per share ("Common Stock")	2,683	$3.05	$8,183.15	Disclosure SEC source: 0001104659-25-063693 · tm2519252-7_4seq1.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 50,949 F1 · shares: The shares reported as disposed herein were granted on June 20, 2024 as restricted stock units ("RSUs"). The disposition of shares is associated with tax obligations of the reporting person associated with the vesting of the RSUs. F2 · price: The price reported reflects the weighted average sales price. These shares were sold in multiple transactions at prices ranging from $2.98 to $3.11, inclusive. The reporting person hereby undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
June 24, 2025 Filed Jun 26, 2025 21:15 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantStock Option (Right to Buy) · Derivative	36,797	$0.00 Strike: $3.22	$0.00	Disclosure SEC source: 0001104659-25-063094 · tm2519252-2_4seq1.xml · derivative · entry 2 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,797 Underlying: Common Stock · 36,797 shares Expires 2035-06-24 F2 · derivative.exercise_date: The stock options will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates. Read SEC document
June 24, 2025 Filed Jun 26, 2025 21:15 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantCommon Stock, par value $0.0001 per share ("Common Stock")	12,422	$0.00	$0.00	Disclosure SEC source: 0001104659-25-063094 · tm2519252-2_4seq1.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 53,632 F1 · shares: Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on June 24, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates. Read SEC document
September 10, 2024 Filed Sep 10, 2024 23:43 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	SaleCommon Stock	1,800	$5.34	$9,612.00	Disclosure SEC source: 0001104659-24-098692 · tm2423769-1_4seq1.xml · nonDerivative · entry 3 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 41,210 F1 · shares: The shares reported as disposed herein were granted on July 20, 2023 as restricted stock units ("RSUs"). The disposition of shares is associated with tax obligations of the reporting person associated with the vesting of the RSUs. F4 · price: The price reported reflects the weighted average sales price. These shares were sold in multiple transactions at prices ranging from $5.14 to $5.69, inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 09, 2024 Filed Sep 10, 2024 23:43 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	SaleCommon Stock	1,800	$5.43	$9,774.00	Disclosure SEC source: 0001104659-24-098692 · tm2423769-1_4seq1.xml · nonDerivative · entry 2 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 43,010 F1 · shares: The shares reported as disposed herein were granted on July 20, 2023 as restricted stock units ("RSUs"). The disposition of shares is associated with tax obligations of the reporting person associated with the vesting of the RSUs. F3 · price: The price reported reflects the weighted average sales price. These shares were sold in multiple transactions at prices ranging from $5.38 to $5.53, inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 06, 2024 Filed Sep 10, 2024 23:43 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	SaleCommon Stock, par value $0.0001 per share ("Common Stock")	2,000	$5.64	$11,280.00	Disclosure SEC source: 0001104659-24-098692 · tm2423769-1_4seq1.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 44,810 F1 · shares: The shares reported as disposed herein were granted on July 20, 2023 as restricted stock units ("RSUs"). The disposition of shares is associated with tax obligations of the reporting person associated with the vesting of the RSUs. F2 · price: The price reported reflects the weighted average sales price. These shares were sold in multiple transactions at prices ranging from $5.54 to $5.78, inclusive. The reporting person hereby undertakes to provide upon request to the staff of the Securities and Exchange Commission (the "SEC"), the Issuer or any security holder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
June 20, 2024 Filed Jun 21, 2024 21:55 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantStock Option (Right to Buy) · Derivative	17,068	$0.00 Strike: $7.44	$0.00	Disclosure SEC source: 0001104659-24-074010 · tm2417742-2_4seq1.xml · derivative · entry 2 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 17,068 Underlying: Common Stock · 17,068 shares Expires 2034-06-20 Read SEC document
June 20, 2024 Filed Jun 21, 2024 21:55 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantCommon Stock, par value $0.0001 per share ("Common Stock")	5,376	$0.00	$0.00	Disclosure SEC source: 0001104659-24-074010 · tm2417742-2_4seq1.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 46,810 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest on June 20, 2025. Read SEC document
July 20, 2023 Filed Jul 24, 2023 21:08 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantStock Option (Right to Buy) · Derivative	17,500	$0.00 Strike: $7.42	$0.00	Disclosure SEC source: 0001104659-23-083495 · tm2321855-1_4seq1.xml · derivative · entry 2 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2033-07-20 Read SEC document
July 20, 2023 Filed Jul 24, 2023 21:08 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantCommon Stock, par value $0.0001 per share ("Common Stock")	11,667	$0.00	$0.00	Disclosure SEC source: 0001104659-23-083495 · tm2321855-1_4seq1.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 41,434 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest on the first anniversary of the grant date. Read SEC document
May 10, 2023 Filed May 12, 2023 20:59 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	Exercise / conversionWarrant (Right to Buy) · Derivative	2,906	$0.00 Strike: $1.08	$0.00	Disclosure SEC source: 0001213900-23-039101 · ownership.xml · derivative · entry 2 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 0 Underlying: Common Stock · 2,906 shares Expires 2023-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 10, 2023 Filed May 12, 2023 20:59 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	Exercise / conversionCommon Stock, par value $0.0001 per share ("Common Stock")	2,906	$1.08	$3,138.48	Disclosure SEC source: 0001213900-23-039101 · ownership.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 29,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 12, 2023 Filed May 6, 2023 00:14 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	Exercise / conversionRight to Receive Earnout Shares · Derivative	4,796	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-23-037021 · ownership.xml · derivative · entry 2 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 4,796 Underlying: Common Stock · 4,796 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and 4,796 shares of Common Stock were issued to the Fain Living Trust on April 19, 2023 in accordance with the Merger Agreement. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 4,796 shares of Common Stock were issued to the Fain Living Trust on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 4,796 shares of Common Stock were issued to the Fain Living Trust on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and 4,796 shares of Common Stock were issued to the Fain Living Trust on April 19, 2023 in accordance with the Merger Agreement. F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and 4,796 shares of Common Stock were issued to the Fain Living Trust on April 19, 2023 in accordance with the Merger Agreement. Read SEC document
April 12, 2023 Filed May 6, 2023 00:14 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	Exercise / conversionCommon Stock, par value $0.0001 per share ("Common Stock")	4,796	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-23-037021 · ownership.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 26,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 4,796 shares of Common Stock were issued to the Fain Living Trust on April 19, 2023 in accordance with the Merger Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 4,796 shares of Common Stock were issued to the Fain Living Trust on April 19, 2023 in accordance with the Merger Agreement. Read SEC document
January 26, 2023 Filed Jan 31, 2023 02:29 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantWarrant (Right to Buy) · Derivative	2,906	Not disclosed Strike: $1.08	Not disclosed	Disclosure SEC source: 0001213900-23-006184 · ownership.xml · derivative · entry 5 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 2,906 Underlying: Common Stock · 2,906 shares Expires 2023-05-31 F7 · price: Received in the Business Combination in exchange for warrants to purchase 6,250 shares of Legacy Orchestra Common Stock for $0.50 per share. Read SEC document
January 26, 2023 Filed Jan 31, 2023 02:29 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantNonstatutory Stock Option (Right to Buy) · Derivative	23,250	Not disclosed Strike: $10.00	Not disclosed	Disclosure SEC source: 0001213900-23-006184 · ownership.xml · derivative · entry 4 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 23,250 Underlying: Common Stock · 23,250 shares Expires 2032-08-25 F6 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 50,000 shares of Legacy Orchestra Common Stock for $4.65 per share. F5 · derivative.exercise_date: The nonstatutory stock options vest over a three-year period as follows: (i) 33% of the underlying shares will vest on the first anniversary of the grant date and (ii) 67% of the underlying shares have vested and will vest in equal installments on a quarterly basis, starting on the day of the month of the last month of the first quarter after the first anniversary of the grant date, that is the same day of the month as the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022. Read SEC document
January 26, 2023 Filed Jan 31, 2023 02:29 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantNonstatutory Stock Option (Right to Buy) · Derivative	6,975	Not disclosed Strike: $4.30	Not disclosed	Disclosure SEC source: 0001213900-23-006184 · ownership.xml · derivative · entry 3 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 6,975 Underlying: Common Stock · 6,975 shares Expires 2029-08-06 F4 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 15,000 shares of Legacy Orchestra Common Stock for $2.00 per share. Read SEC document
January 26, 2023 Filed Jan 31, 2023 02:29 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantNonstatutory Stock Option (Right to Buy) · Derivative	18,600	Not disclosed Strike: $4.30	Not disclosed	Disclosure SEC source: 0001213900-23-006184 · ownership.xml · derivative · entry 2 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 18,600 Underlying: Common Stock · 18,600 shares Expires 2028-11-16 F3 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 40,000 shares of Legacy Orchestra Common Stock for $2.00 per share. Read SEC document
January 26, 2023 Filed Jan 31, 2023 02:29 UTC	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantCommon Stock, par value $0.0001 per share ("Common Stock")	22,065	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-23-006184 · ownership.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 22,065 F1 · shares: These securities were issued on the closing date of the merger (the "Business Combination") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the "Merger Agreement"), by and among Orchestra BioMed Holdings, Inc. (f/k/a Health Sciences Acquisitions Corporation 2) ("HSAC2"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation ("Legacy Orchestra"), in exchange for Legacy Orchestra securities. F2 · price: Received in the Business Combination in exchange for 47,450 shares of common stock of Legacy Orchestra ("Legacy Orchestra Common Stock"). Read SEC document
January 26, 2023 Filed May 5, 2023 23:47 UTC Amendment	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantRight to Receive Earnout Shares · Derivative	9,592	Not disclosed	Not disclosed	Disclosure SEC source: 0001213900-23-037004 · ownership.xml · derivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 9,592 Underlying: Common Stock · 9,592 shares Expires not disclosed F1 · security: On January 30, 2023, the Reporting Person filed a Form 4 which inadvertently omitted the right to receive Earnout Shares (defined below). In accordance with Instruction 9(a) to Form 4, this amendment is filed solely to add the lines of information to Table II included here; as provided in that instruction, the remainder of the information in the original filing is not restated in this amendment, and no other amendment is made to the original filing. F2 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period. Read SEC document
January 26, 2023 Filed May 19, 2023 21:48 UTC Amendment	Orchestra BioMed Holdings, Inc. OBIO · Entity 434	GrantNonstatutory Stock Option (Right to Buy) · Derivative	23,250	Not disclosed Strike: $10.00	Not disclosed	Disclosure SEC source: 0001213900-23-041625 · ownership.xml · derivative · entry 1 Fain Eric S · CIK 0001402222 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Fain Living Trust Disclosed balance after: 23,250 Underlying: Common Stock · 23,250 shares Expires 2032-08-17 F1 · security: On January 30, 2023, the Reporting Person filed a Form 4 which inadvertently misstated the expiration date of one class of nonstatutory stock options ("NSOs"). In accordance with Instruction 9(b) to Form 4, this amendment is filed solely to correct the incorrect expiration date in Table II, Column 6 to August 17, 2032; as provided in that instruction, the remainder of the information in the original filing is not restated in this amendment, and no other amendment is made to the original filing. F3 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 50,000 shares of Legacy Orchestra Common Stock for $4.65 per share. F2 · derivative.exercise_date: The NSOs vest over a three-year period as follows: (i) 33% of the underlying shares will vest on the first anniversary of the grant date and (ii) 67% of the underlying shares have vested and will vest in equal installments on a quarterly basis, starting on the day of the month of the last month of the first quarter after the first anniversary of the grant date, that is the same day of the month as the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022. Read SEC document
July 21, 2017 Filed Jul 25, 2017 22:38 UTC	ABBOTT LABORATORIES ABT · Entity 2314	Tax withholdingCommon shares without par value	1,524	$50.84	$77,480.16	Disclosure SEC source: 0001179110-17-010671 · edgar.xml · nonDerivative · entry 2 Fain Eric S · CIK 0001402222 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,046 Read SEC document
July 21, 2017 Filed Jul 25, 2017 22:38 UTC	ABBOTT LABORATORIES ABT · Entity 2314	Tax withholdingCommon shares without par value	26,488	$50.85	$1,346,914.80	Disclosure SEC source: 0001179110-17-010671 · edgar.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 518,570 Read SEC document
July 21, 2017 Filed Sep 29, 2017 21:10 UTC Amendment	ABBOTT LABORATORIES ABT · Entity 2314	Disposition to issuerCommon shares without par value	23,085	$0.00	$0.00	Disclosure SEC source: 0001179110-17-012768 · edgar.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,961 Read SEC document
February 17, 2017 Filed Feb 22, 2017 22:19 UTC	ABBOTT LABORATORIES ABT · Entity 2314	GrantOption (right to buy) · Derivative	159,657	$0.00 Strike: $44.40	$0.00	Disclosure SEC source: 0001179110-17-002920 · edgar.xml · derivative · entry 2 Fain Eric S · CIK 0001402222 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,657 Underlying: Common shares · 159,657 shares Expires 2027-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 53,219 on 02/17/2018, 53,219 on 02/17/2019, and 53,219 on 02/17/2020. Read SEC document
February 17, 2017 Filed Feb 22, 2017 22:19 UTC	ABBOTT LABORATORIES ABT · Entity 2314	GrantCommon shares without par value	23,085	$0.00	$0.00	Disclosure SEC source: 0001179110-17-002920 · edgar.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,052 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. F2 · balance_after: Due to administrative error, the previously reported beneficial ownership for this reporting person was overstated by 1 share. This Form 4 reflects the corrected total beneficial ownership for this reporting person. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:11 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerRestricted Stock Units · Derivative	8,316	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-000586 · edgar.xml · derivative · entry 11 Fain Eric S · CIK 0001402222 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,316 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:11 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	104,408	Not disclosed Strike: $61.62	Not disclosed	Disclosure SEC source: 0001179110-17-000586 · edgar.xml · derivative · entry 10 Fain Eric S · CIK 0001402222 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 104,408 shares Expires 2023-12-07 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:11 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerRestricted Stock Units · Derivative	4,678	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-000586 · edgar.xml · derivative · entry 9 Fain Eric S · CIK 0001402222 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,678 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:11 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	82,364	Not disclosed Strike: $69.08	Not disclosed	Disclosure SEC source: 0001179110-17-000586 · edgar.xml · derivative · entry 8 Fain Eric S · CIK 0001402222 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 82,364 shares Expires 2022-12-08 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:11 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerRestricted Stock Units · Derivative	2,554	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-000586 · edgar.xml · derivative · entry 7 Fain Eric S · CIK 0001402222 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,554 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:11 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	85,156	Not disclosed Strike: $59.41	Not disclosed	Disclosure SEC source: 0001179110-17-000586 · edgar.xml · derivative · entry 6 Fain Eric S · CIK 0001402222 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,156 shares Expires 2021-12-10 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:11 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	150,000	Not disclosed Strike: $35.27	Not disclosed	Disclosure SEC source: 0001179110-17-000586 · edgar.xml · derivative · entry 5 Fain Eric S · CIK 0001402222 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2020-12-10 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:11 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	200,000	Not disclosed Strike: $34.96	Not disclosed	Disclosure SEC source: 0001179110-17-000586 · edgar.xml · derivative · entry 4 Fain Eric S · CIK 0001402222 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2019-12-12 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:11 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	144,500	Not disclosed Strike: $41.65	Not disclosed	Disclosure SEC source: 0001179110-17-000586 · edgar.xml · derivative · entry 3 Fain Eric S · CIK 0001402222 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 144,500 shares Expires 2018-12-14 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:11 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	140,000	Not disclosed Strike: $38.59	Not disclosed	Disclosure SEC source: 0001179110-17-000586 · edgar.xml · derivative · entry 2 Fain Eric S · CIK 0001402222 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 140,000 shares Expires 2017-12-14 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:11 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerCommon Stock	130,716	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-000586 · edgar.xml · nonDerivative · entry 1 Fain Eric S · CIK 0001402222 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. Read SEC document
January 04, 2017 Filed Jan 6, 2017 22:28 UTC	ABBOTT LABORATORIES ABT · Entity 2314	GrantOption (right to buy) · Derivative	163,268	Not disclosed Strike: $29.56	Not disclosed	Disclosure SEC source: 0001104659-17-001246 · a4.xml · derivative · entry 7 Fain Eric S · CIK 0001402222 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,268 Underlying: Common shares without par value · 163,268 shares Expires 2023-12-07 F7 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio. F7 · derivative.exercise_date: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio. F10 · derivative.exercise_date: 54,422 options are scheduled to vest on December 17, 2017, 54,422 options are scheduled to vest on December 17, 2018 and 54,424 options are scheduled to vest on January 4, 2019. Read SEC document
January 04, 2017 Filed Jan 6, 2017 22:28 UTC	ABBOTT LABORATORIES ABT · Entity 2314	GrantOption (right to buy) · Derivative	85,864	Not disclosed Strike: $33.14	Not disclosed	Disclosure SEC source: 0001104659-17-001246 · a4.xml · derivative · entry 6 Fain Eric S · CIK 0001402222 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,864 Underlying: Common shares without par value · 85,864 shares Expires 2022-12-08 F7 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio. F7 · derivative.exercise_date: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio. F9 · derivative.exercise_date: 42,932 options are scheduled to vest on December 17, 2017 and 42,932 options are scheduled to vest on December 17, 2018. Read SEC document
January 04, 2017 Filed Jan 6, 2017 22:28 UTC	ABBOTT LABORATORIES ABT · Entity 2314	GrantOption (right to buy) · Derivative	44,387	Not disclosed Strike: $28.50	Not disclosed	Disclosure SEC source: 0001104659-17-001246 · a4.xml · derivative · entry 5 Fain Eric S · CIK 0001402222 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,387 Underlying: Common shares without par value · 44,387 shares Expires 2021-12-10 F7 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio. F7 · derivative.exercise_date: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio. F8 · derivative.exercise_date: These options are scheduled to vest on December 17, 2017. Read SEC document
January 04, 2017 Filed Jan 6, 2017 22:28 UTC	ABBOTT LABORATORIES ABT · Entity 2314	GrantCommon shares without par value	32,418	$0.00	$0.00	Disclosure SEC source: 0001104659-17-001246 · a4.xml · nonDerivative · entry 4 Fain Eric S · CIK 0001402222 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,968 F5 · shares: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical restricted stock unit award was canceled and converted into a restricted stock unit award, with substantially the same terms and conditions as were applicable to such St. Jude Medical award (except that, subject to the holder's continued employment, the award will fully vest to the extent unvested on the second anniversary of the First Effective Time), that is settleable with respect to a number of Abbott common shares equal to the product (rounded to the nearest whole share) of (a) the number of St. Jude Medical shares subject to such award multiplied by (b) 2.0850 (the "Stock Award Exchange Ratio"). F6 · shares: 15,982 restricted stock units are scheduled to vest on December 17, 2017 and will be settled promptly thereafter, 10,657 restricted stock units are scheduled to vest on December 17, 2018 and will be settled promptly thereafter, and 5,779 restricted stock units are scheduled to vest on January 4, 2019 and will be settled December 17, 2019. Read SEC document
January 04, 2017 Filed Jan 6, 2017 22:28 UTC	ABBOTT LABORATORIES ABT · Entity 2314	GrantCommon shares without par value	50,761	$0.00	$0.00	Disclosure SEC source: 0001104659-17-001246 · a4.xml · nonDerivative · entry 3 Fain Eric S · CIK 0001402222 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 488,549 F4 · shares: These shares represent restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. These awards have a 3-year term and are scheduled to vest on January 4, 2020. The award includes the right to have shares withheld for tax purposes. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.